• In a recent human clinical trial, HYPER-H21-2, DehydraTECH
  
  -CBD reduced arterial stiffness, potentially broadening Lexaria’s application’s ability to treat cardiovascular and other diseases beyond hypertension
• Lexaria’s patented technology DehydraTECH improves how APIs enter the bloodstream –making multiple benefits possible such as increased delivery speed, increase in brain absorbency, higher bioavailability, and lower costs
• The company has patent protection received for delivery of nicotine, vitamins, NSAIDs, terpenes, and cannabinoids; and patents pending for delivery of estrogen, testosterone, PDE5 inhibitors, antiviral drugs, and more

Oral absorption is the most convenient and widely used administration route for taking medications. Decades of research have advanced the understanding of critical factors – anatomical, physiological, and drug information – which control oral bioavailability. Scientists are now better understanding the physiological function and formulation functionality that has been used in designing better and more desirable oral medicine delivery through extensive research. Lexaria Bioscience (NASDAQ:LEXX), a global innovator of drug delivery platforms, is accomplishing this through its patented DehydraTECH(TM) technology.

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. The content was purely for informational purposes only and not intended to be investing advice.